Literature DB >> 4830225

Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

R J Lewis, W F Trager, K K Chan, A Breckenridge, M Orme, M Roland, W Schary.   

Abstract

An examination of the metabolic fate of the R and the S isomers of warfarin revealed that the two isomers were metabolized by different routes. R warfarin was oxidized to 6-hydroxywarfarin and was reduced to the (R,S) warfarin alcohol. In contrast, S warfarin was oxidized to 7-hydroxywarfarin and was reduced to the (S,S) warfarin alcohol. S warfarin was also oxidized to 6-hydroxywarfarin. These observations suggested that interactions between warfarin and other drugs might be manifest stereo-specifically, i.e., have a different effect on the isomers of warfarin, so a series of experiments were conducted with each isomer of warfarin, before and after phenylbutazone. The plasma clearance of S warfarin was slowed from 3.1 to 1.1% per h in one subject and from 2.3 to 1.6% per h in another. In contrast, the clearance of R warfarin was increased from 1.5 to 3.0% per h and from 0.9 to 1.6% per h in two subjects after phenylbutazone. The rate of clearance of racemic warfarin was unaffected by phenylbutazone; the depression of the rate of clearance of the S isomer masked the stimulation of the clearance of the R isomer. Since S warfarin is five times more potent an anticoagulant than R warfarin, it is concluded that inhibition of the metabolism of S warfarin provides one mechanism for the augmented anticoagulation which follows phenylbutazone.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4830225      PMCID: PMC302656          DOI: 10.1172/JCI107711

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  The metabolism of R(+)- and RS-pentobarbital.

Authors:  K H Palmer; M S Fowler; M E Wall; L S Rhodes; W J Waddell; B Baggett
Journal:  J Pharmacol Exp Ther       Date:  1969-12       Impact factor: 4.030

2.  Mass spectral analysis in the identification of human metabolites of warfarin.

Authors:  W F Trager; R J Lewis; W A Garland
Journal:  J Med Chem       Date:  1970-11       Impact factor: 7.446

3.  Metabolism of optically active barbiturates. II. S (-)--pentobarbital.

Authors:  K H Palmer; M S Fowler; M E Wall
Journal:  J Pharmacol Exp Ther       Date:  1970-10       Impact factor: 4.030

4.  Stereoselective metabolism of the enantiomers of hexobarbital.

Authors:  R L Furner; J S McCarthy; R E Stitzel; M W Anders
Journal:  J Pharmacol Exp Ther       Date:  1969-10       Impact factor: 4.030

5.  The nature of the metabolites of acetohexamide in the rat and in the human.

Authors:  R E McMahon; F J Marshall; H W Culp
Journal:  J Pharmacol Exp Ther       Date:  1965-08       Impact factor: 4.030

6.  The effect of various drugs on the binding of warfarin-14C to human albumin.

Authors:  H M Solomon; J J Schrogie
Journal:  Biochem Pharmacol       Date:  1967-07-07       Impact factor: 5.858

7.  Potentiation of acetohexamide hypoglycemia by phenylbutazone.

Authors:  J B Field; M Ohta; C Boyle; A Remer
Journal:  N Engl J Med       Date:  1967-10-26       Impact factor: 91.245

8.  Potentiation of anticoagulant effect of warfarin by phenylbutazone.

Authors:  P M Aggeler; R A O'Reilly; L Leong; P E Kowitz
Journal:  N Engl J Med       Date:  1967-03-02       Impact factor: 91.245

9.  Warfarin metabolism in man: identification of metabolites in urine.

Authors:  R J Lewis; W F Trager
Journal:  J Clin Invest       Date:  1970-05       Impact factor: 14.808

10.  Synthesis and relative urinary excretion rates of the enantiomers of warfarin-4-14C and phenprocoumon-2-14C.

Authors:  L A Goding; B D West
Journal:  J Med Chem       Date:  1969-05       Impact factor: 7.446

View more
  73 in total

Review 1.  Progress in clinical pharmacology over the last 20 years.

Authors:  Michel Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

Review 2.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 3.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Applying organ clearance concepts in a clinical setting.

Authors:  Jorge Duconge
Journal:  Am J Pharm Educ       Date:  2008-10-15       Impact factor: 2.047

6.  Metabolism of the aldose reductase inhibitor ALO1567 in man.

Authors:  Y H Park; J E Hudson; R C Barker; B M York; R K Brazzell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

7.  LC-MS-MS Analysis of Brodifacoum Isomers in Rat Tissue.

Authors:  Zane Z Hauck; Douglas L Feinstein; Richard B van Breemen
Journal:  J Anal Toxicol       Date:  2016-02-23       Impact factor: 3.367

8.  Lack of interaction between meloxicam and warfarin in healthy volunteers.

Authors:  D Türck; C A Su; G Heinzel; U Busch; E Bluhmki; J Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

9.  Stereoselective renal clearance of pindolol in humans.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

10.  Enhanced elimination of warfarin during treatment with cholestyramine.

Authors:  E Jähnchen; T Meinertz; H J Gilfrich; F Kersting; U Groth
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.